<DOC>
	<DOCNO>NCT01887379</DOCNO>
	<brief_summary>Furosemide diuretic drug , use treatment oedematous state associate cardiac , renal , hepatic disorder , may effective patient unresponsive thiazide diuretic . Furosemide also use treatment hypertension . Absorption furosemide gastrointestinal tract fairly rapid ; bioavailability 60-70 % , variable predictable , large intra- inter-individual variability , influenced dosage form , underlying disease , presence food oral administration . Data animal model show furosemide administer stomach rapidly absorb administer small intestine . To increase residency furosemide stomach oral administration , gastroretentive dosage form ( GRDF ) furosemide develop . In current study , new formulation ( 30mg furosemide coated tablet ) test healthy male subject . Absorption characterise effective safe imaging technique - Magnetic Marker Monitoring ( MMM ) , base Fe3O4 add drug product generate magnetic signal use 12 h furosemide administration localize medication gastrointestinal tract . Fe3O4 frequently use colour pigment medicinal product . It exhibit pharmacodynamic activity consider inactive ingredient . In current study , GRDF formulation furosemide evaluate : gastric residence well pharmacokinetic pharmacodynamic characteristic fast fed condition . As part study , subject hospitalized 1 day drug administration . The duration stay depend intestinal behaviour investigational product .</brief_summary>
	<brief_title>Magnetic Marker Monitoring Furosemide-containing Gastroretentive Formulation Healthy Male Subjects ( Fasting Fed Conditions )</brief_title>
	<detailed_description>Furosemide diuretic drug , widely use treatment oedematous state associate cardiac , renal , hepatic disorder , may effective patient unresponsive thiazide diuretic . Furosemide also use treatment hypertension . Absorption furosemide gastrointestinal tract fairly rapid . Bioavailability report 60-70 % , variable predictable . The rate extent absorption show large intra- inter-individual variability influence dosage form , underlying disease , presence food oral administration . Results obtain animal model indicate furosemide administer stomach rapidly absorb administer small intestine . To increase residency furosemide stomach oral administration , gastroretentive dosage form ( GRDF ) furosemide develop . In study , new formulation ( 30mg furosemide coated tablet ) test healthy male subject . Absorption characterise image technique - Magnetic Marker Monitoring ( MMM ) , effective safe imaging technique currently available . MMM base iron-III-oxide ( Fe3O4 ) add drug product generate magnetic signal use localize administered medication gastrointestinal tract . Fe3O4 frequently use colour pigment medicinal product . It exhibit pharmacodynamic activity thus , consider clinically inactive ingredient . Fe3O4 exhibit dipole moment thus , magnetisation solid oral dosage form contain homogenously distribute Fe3O4 , product generates magnetic signal , use localisation dosage form gastrointestinal tract Magnetic Marker Monitoring technique . The aim current study evaluate GRDF formulation furosemide : gastric residence , pharmacokinetic pharmacodynamic characteristic fast fed condition . As part study , subject hospitalized 1 day drug administration ( i.e . total two day ) . The duration stay depend intestinal behaviour investigational product . The MMM monitoring perform 12 h furosemide administration . For pharmacokinetic determination , liquid chromatography couple tandem mass spectrometry ( LC-MS/MS ) use analyze furosemide plasma .</detailed_description>
	<mesh_term>Furosemide</mesh_term>
	<criteria>1. sex : male 2. ethnic origin : Caucasian 3. age : 18 year 55 year 4. bodymass index ( BMI ) : &gt; = 19 kg/m² &lt; = 27 kg/m² 5. good state health 6. nonsmoker exsmoker least 1 month 7. write informed consent , inform benefit potential risk clinical trial , well detail insurance take cover subject participate clinical trial 1. exist cardiac and/or haematological disease pathological finding , might interfere safety tolerability active ingredient 2. exist hepatic and/or renal disease pathological finding , might interfere safety tolerability active ingredient 3. exist gastrointestinal disease pathological finding , might interfere safety tolerability gastric empty gastrointestinal transport ( e.g . inflammatory bowel disease , ileus ) 4. history relevant central nervous system ( CNS ) and/or psychiatric disorder and/or currently treat CNS and/or psychiatric disorder 5. surgery gastrointestinal tract , might interfere safety test product stomach reduction like Bioenterics Intragastric Balloon ( BIB ) gastric band 6. know allergic reaction active ingredient use constituent pharmaceutical preparation 7. know allergic reaction sulphonamide 8. subject severe allergy multiple drug allergy unless judge relevant clinical trial investigator 9. heart rate &lt; 50 bpm &gt; 90 bpm 10. systolic blood pressure &lt; 100 mmHg &gt; 140 mmHg , diastolic blood pressure &lt; 60 mmHg &gt; 90 mmHg 11. laboratory value , especially sodium , potassium , calcium , creatinine , urea , uric acid , blood glucose normal range unless deviation normal judge relevant clinical trial investigator 12. positive antihuman immunodeficiency virustest ( positive verify western blot ) , surface antigen hepatitis B virus ( HBsAG ) test [ positive verified test hepatitis B Core ( HBcIgM ) ] antihepatitis C virustest 13. renal failure anuria 14. coma praecoma hepatica 15. severe hypokalemia and/or hyponatremia 16. hypovolemia dehydration 17. subject manifest latent diabetes mellitus gout 18. subject cerebrovascular insufficiency coronary heart disease 19. subject bladder outlet obstruction ( BOO ) e.g . prostatic hypertrophy , hydronephrosis ureteral stenosis 20. hypoproteinemia 21. liver cirrhosis simultaneous limitation kidney function 22. acute chronic disease could affect gastric empty gastrointestinal transport 23. history current drug alcohol dependence 24. positive alcohol drug test screen examination 25. regular intake alcoholic food beverage ≥ 40 g pure ethanol male per day 26. subject diet could affect gastric empty gastrointestinal transport 27. regular intake caffeine contain food beverage ≥ 500 mg caffeine per day 28. subject claustrophobia 29. ferromagnetic implant magnetic disturbance , affect Magnetic Marker Monitoring measurement 30. blood donation blood loss 400 ml within last two month prior individual enrolment subject 31. participation clinical trial last two month prior individual enrolment subject 32. regular treatment systemically available medication include ototoxic medication like aminoglycosides medication could affect gastric empty gastrointestinal transport ( e.g . laxative , metoclopramide , loperamide , antacid , H2receptor antagonists ) antibiotic 33. subject , report frequent occurrence migraine attack 34. subject suspect know follow instruction 35. subject unable understand write verbal instruction , particular regard risk inconvenience expose participation clinical trial 36. subject forfeit freedom administrative legal award , guardianship admit sanitary social institution</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Gastroretentive drug formulation</keyword>
	<keyword>Furosemide</keyword>
	<keyword>Magnetic Marker Monitoring</keyword>
	<keyword>Magnetic marker</keyword>
	<keyword>Oedema</keyword>
</DOC>